Kenneth Hoberman
Chief Operating Officer presso STEMLINE THERAPEUTICS, INC.
Patrimonio netto: 4 M $ in data 31/03/2024
Profilo
Kenneth Hoberman is currently the Vice Chairman at Lirum Therapeutics, Inc., an Independent Director at TG Therapeutics, Inc., an Independent Director at Nuvectis Pharma, Inc., and the Secretary & Chief Operating Officer at Stemline Therapeutics, Inc. Previously, he served as the Vice President-Corporate & Business Development at Keryx Biopharmaceuticals, Inc. from 2004 to 2012.
Mr. Hoberman completed his undergraduate degree at Boston University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
TG THERAPEUTICS, INC.
0.16% | 28/09/2023 | 242 685 ( 0.16% ) | 4 M $ | 31/03/2024 |
NUVECTIS PHARMA, INC.
0.41% | 16/06/2023 | 73 140 ( 0.41% ) | 599 748 $ | 31/03/2024 |
Posizioni attive di Kenneth Hoberman
| Società | Posizione | Inizio |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Chief Operating Officer | 01/01/2013 |
| TG THERAPEUTICS, INC. | Director/Board Member | 15/12/2014 |
| NUVECTIS PHARMA, INC. | Director/Board Member | 01/07/2021 |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Director/Board Member | 01/11/2021 |
Precedenti posizioni note di Kenneth Hoberman
| Società | Posizione | Fine |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Corporate Officer/Principal | 01/01/2012 |
Formazione di Kenneth Hoberman
| Boston University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| TG THERAPEUTICS, INC. | Health Technology |
| NUVECTIS PHARMA, INC. | Health Technology |
 | Health Technology |
| Aziende private | 2 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Kenneth Hoberman
